Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
Reporting from:
ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005
In this edition:
Martine Piccart gave the Paris ECCO conference her
Post a comment